Potential new drug target to treat cutaneous T cell lymphoma

In order to improve their understanding of how CTCL develops in hopes of developing new therapies, a team of scientists conducted a series of studies. They demonstrate that decreased expression of the protein SATB1 contributes to CTCL development and that drugs that cause SATB1 to become re-expressed may be potential treatment options for this disease.